Treatment of Low-Blast Count AML using Hypomethylating Agents

In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS). However, this AML subtype, defined as low-blast count AML (LBC-AML,...

Descripción completa

Detalles Bibliográficos
Autores principales: De Bellis, Eleonora, Fianchi, Luana, Buccisano, Francesco, Criscuolo, Marianna, Maurillo, Luca, Cicconi, Laura, Brescini, Mattia, Del Principe, Maria Ilaria, Di Veroli, Ambra, Venditti, Adriano, Amadori, Sergio, Arcese, William, Lo-Coco, Francesco, Voso, Maria Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499495/
https://www.ncbi.nlm.nih.gov/pubmed/28698788
http://dx.doi.org/10.4084/MJHID.2017.045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499495/
https://www.ncbi.nlm.nih.gov/pubmed/28698788
http://dx.doi.org/10.4084/MJHID.2017.045

Ejemplares similares